We noted a considerable increase in the percentage of CD8+T cells infiltrated the primary tumor upon triple therapies (46.7% ± 0.9%), which was significantly higher than the obtained for the GI (7.0% ± 0.6%), GII (20.7% ± 1.5%), or GIII (23.5% ± 1.0%) groups (Figure 8G). The gene discussed is CD8A; the disease is neoplasm.